316 / 884
Low Risk and favourable Intermediate Risk
5 studies
- 4 studies describing outcome in patients treated with LDR +/- ADT
- 1 study describing outcome in patients treated with LDR +/- EBRT +/- ADT
ADT used in 27-65% of patients
ADT duration 3-6 mths
Most often: downside prostate volume before BT and in one study for IR features
•
None of the studies showed any benefit from ADT to bPFS.
•
Effect on CSS not reported
•
Not associated with improved or detrimental OS